Role of immune escape mechanisms in Hodgkin's lymphoma development and progression: A whole new world with therapeutic implications

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  De La Cruz Merino, Luis ^a   Lejeune, Marylène ^b   Nogales Fernández, Esteban ^a   Henao Carrasco, Fernando ^a   Grueso López, Ana ^a   Illescas Vacas, Ana ^a   Pulla, Mariano Provencio ^c   Callau, Cristina ^b   Álvaro, Tomás ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^c HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BIOLOGICAL FACTOR; BRENTUXIMAB VEDOTIN; CANCER VACCINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; GEMCITABINE; IBRITUMOMAB TIUXETAN; IPILIMUMAB; LENALIDOMIDE; RITUXIMAB; THALIDOMIDE DERIVATIVE; TOSITUMOMAB I 131; CYTOKINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER THERAPY; CELL TYPE; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG TARGETING; EXTRACELLULAR MATRIX; HEMATOPOIESIS; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REED STERNBERG CELL; REGULATORY T LYMPHOCYTE; TREATMENT INDICATION; TREATMENT PLANNING; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; TUMOR MICROENVIRONMENT; VACCINATION; VIRUS INFECTION; BLOOD; DENDRITIC CELL; DISEASE COURSE; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; LYMPHOCYTE; MACROPHAGE; METABOLISM; NATURAL KILLER CELL; NEUTROPHIL; PATHOLOGY; REVIEW; TUMOR ESCAPE;

CYTOKINES; DENDRITIC CELLS; DISEASE PROGRESSION; HODGKIN DISEASE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOTHERAPY; KILLER CELLS, NATURAL; LYMPHOCYTES; MACROPHAGES; NEUTROPHILS; REED-STERNBERG CELLS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84866054013     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/756353     Document Type: Article

References (267)

1. Küppers R., Molecular biology of Hodgkin's lymphoma. Advances in Cancer Research 2002 84 277 312 2-s2.0-0036189576 10.1016/S0065-230X(02)84009-X (Pubitemid 34188200)
2. Staudt L. M., The molecular and cellular origins of Hodgkin's disease. Journal of Experimental Medicine 2000 191 2 207 212 2-s2.0-0034677122 10.1084/jem.191.2.207 (Pubitemid 30060911)
3. Thomas R. K., Re D., Wolf J., Diehl V., Part I: Hodgkin's lymphomamolecular biology of Hodgkin and Reed-Sternberg cells. Lancet Oncology 2004 5 1 11 18 2-s2.0-0347286872 10.1016/S1470-2045(03)01319-6 (Pubitemid 38072555)
4. Swerdlow S. H., Campo E., Harris N. L., WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008 Lyon, France IARC Press
5. Swinnen L. J., Post-transplant lymphoproliferative disorders: implications for acquired immunodeficiency syndrome-associated malignancies. Journal of the National Cancer Institute. Monographs 2001 28 38 43 2-s2.0-0003026992
6. Aldinucci D., Gloghini A., Pinto A., De Filippi R., Carbone A., The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. Journal of Pathology 2010 221 3 248 263 2-s2.0-77953534075 10.1002/path.2711
7. Poppema S., Immunobiology and pathophysiology of Hodgkin lymphomas. Hematology 2005 231 238 2-s2.0-33646229918
8. Machado L., Jarrett R., Morgan S., Murray P., Hunter B., Hamilton E., Crocker J., Thomas W., Steven N., Ismail T., Chapman A., Adams D. H., Lee S. P., Expression and function of T cell homing molecules in Hodgkin's lymphoma. Cancer Immunology, Immunotherapy 2009 58 1 85 94 2-s2.0-54849416983 10.1007/s00262-008-0528-z
9. Poppema S., Potters M., Visser L., van den Berg A. M., Immune escape mechanisms in Hodgkin's disease. Annals of Oncology 1998 9 supplement 5 S21 S24 2-s2.0-0032448383 (Pubitemid 29049113)
10. Álvaro-Naranjo T., Lejeune M., Salvadó-Usach M. T., Bosch-Príncep R., Reverter-Branchat G., Jaén-Martínez J., Pons-Ferré L. E., Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leukemia and Lymphoma 2005 46 11 1581 1591 2-s2.0-28244446162 10.1080/10428190500220654 (Pubitemid 41700991)
11. Oudejans J. J., Jiwa N. M., Kummer J. A., Ossenkoppele G. J., Van Heerde P., Baars J. W., Kluin P. M., Kluin-Nelemans J. C., Van Diest P. J., Middeldorp J. M., Meijer C. J. L. M., Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood 1997 89 4 1376 1382 2-s2.0-0031043575 (Pubitemid 27080002)
12. Stein H., Delsol G., Pileri S., Classical Hodgkin lymphoma, introduction. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues 2008 Lyon, France IARC 326 329
13. Poppema S., Nodular lymphocyte predominant Hodgkin lymphoma. WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissue 2008 Lyon, France IARC 323 325
14. Stein R., Von Wasielewski R., Poppema S., MacLennan K., Guenova M., Nodular sclerosis classical Hodgkin lymphoma. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues IARC 2008 Lyon, France 330
15. Weiss L., Von Wasielewski R., Delsol G., Poppema S., Stein H., Mixed cellularity classical Hodgkin lymphoma. WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissue 2008 Lyon, France IARC 331
16. Anagnostopoulos I., Isaacson P., Stein H., Lymphocyte rich classical Hodgkin lymphoma. WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissue 2008 Lyon, France IARC 332 333
17. Benharroch D., Stein H., Peh S., Lymphocyte-depleted classical Hodgkin lymphoma. WHO Classification of Tumors of the Hematopoietic and Lymphoid Tissue 2008 Lyon France IARC 334
18. Kapp U., Dux A., Schell-Frederick E., Banik N., Hummel M., Mucke S., Fonatsch C., Bullerdiek J., Gottstein C., Engert A., Diehl V., Wolf J., Disseminated growth of Hodgkin's-derived cell lines L540 and L540cy in immune-deficient SCID mice. Annals of Oncology 1994 5 supplement 1 121 126 2-s2.0-0028079561 (Pubitemid 24051331)
19. Biggar R. J., Jaffe E. S., Goedert J. J., Chaturvedi A., Pfeiffer R., Engels E. A., Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006 108 12 3786 3791 2-s2.0-33845237838 10.1182/blood-2006-05-024109 (Pubitemid 44864560)
20. Aldinucci D., Olivo K., Lorenzon D., Poletto D., Gloghini A., Carbone A., Pinto A., The role of interleukin-3 in classical Hodgkin's disease. Leukemia and Lymphoma 2005 46 3 303 311 2-s2.0-13544271150 10.1080/10428190400013712 (Pubitemid 40220389)
21. Aldinucci D., Lorenzon D., Olivo K., Rapanà B., Gattei V., Interactions between tissue fibroblasts in lymph nodes and Hodgkin/Reed- Sternberg cells. Leukemia and Lymphoma 2004 45 9 1731 1739 2-s2.0-3242888905 10.1080/10428190410001683633 (Pubitemid 38997138)
22. Jundt F., Anagnostopoulos I., Bommert K., Emmerich F., Müller G., Foss H. D., Royer H. D., Stein H., Dörken B., Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 1999 94 6 2065 2071 2-s2.0-0033567914 (Pubitemid 29430423)
23. + naive T cells. Journal of Leukocyte Biology 2007 82 3 576 584 2-s2.0-34548395936 10.1189/jlb.0906565 (Pubitemid 47367148)
24. Álvaro T., Lejeune M., Salvadó M. T., Bosch R., García J. F., Jaén J., Banham A. H., Roncador G., Montalbán C., Piris M. A., Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clinical Cancer Research 2005 11 4 1467 1473 2-s2.0-20044367117 10.1158/1078-0432.CCR-04-1869 (Pubitemid 40315228)
25. + cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. American Journal of Clinical Pathology 2007 128 6 958 965 2-s2.0-38049022492 10.1309/NB3947K383DJ0LQ2
26. Tan T. T., Coussens L. M., Humoral immunity, inflammation and cancer. Current Opinion in Immunology 2007 19 2 209 216 2-s2.0-33847628325 10.1016/j.coi.2007.01.001 (Pubitemid 46356960)
27. Juszczynski P., Ouyang J., Monti S., Rodig S. J., Takeyama K., Abramson J., Chen W., Kutok J. L., Rabinovich G. A., Shipp M. A., The AP1-dependent secretion of galectin-1 by Reed-Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proceedings of the National Academy of Sciences of the United States of America 2007 104 32 13134 13139 2-s2.0-34548740090 10.1073/pnas.0706017104 (Pubitemid 351737605)
28. Skinnider B. F., Mak T. W., The role of cytokines in classical Hodgkin lymphoma. Blood 2002 99 12 4283 4297 2-s2.0-0037097818 10.1182/blood-2002-01- 0099 (Pubitemid 34627193)
29. Gandhi M. K., Moll G., Smith C., Dua U., Lambley E., Ramuz O., Gill D., Marlton P., Seymour J. F., Khanna R., Galectin-1 mediated suppression of Epstein-Barr virus-specific T-cell immunity in classic Hodgkin lymphoma. Blood 2007 110 4 1326 1329 2-s2.0-34548033053 10.1182/blood-2007-01-066100 (Pubitemid 47281432)
30. Newcom S. R., Gu L., Transforming growth factor β 1 messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin's disease. Journal of Clinical Pathology 1995 48 2 160 163 2-s2.0-0028910228
31. + T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. Cancer Research 2006 66 2 1114 1122 2-s2.0-31544464331 10.1158/0008-5472.CAN-05-3252 (Pubitemid 43165980)
32. + T cells in Hodgkin lymphoma. Blood 2007 110 9 3226 3233 2-s2.0-36148946411 10.1182/blood-2006-12-064360 (Pubitemid 350106315)
33. Yamamoto R., Nishikori M., Kitawaki T., Sakai T., Hishizawa M., Tashima M., Kondo T., Ohmori K., Kurata M., Hayashi T., Uchiyama T., PD-1 PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 2008 111 6 3220 3224 2-s2.0-42449147063 10.1182/blood-2007-05- 085159
34. Álvaro T., de la Cruz-Merino L., Henao-Carrasco F., Villar Rodríguez J. L., Vicente Baz D., Codes M., Provencio M., Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes. Journal of Biomedicine and Biotechnology 2010 2010 17 2-s2.0-77956779733 10.1155/2010/846872 846872
35. Noguera R., Nieto O. A., Tadeo I., Farinas F., Alvaro T., Extracellular matrix, biotensegrity and tumor microenvironment. An update and overview. Histology and Histopathology 2012 27 6 693 705
36. Cabannes E., Khan G., Aillet F., Jarrett R. F., Hay R. T., Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for I κ B α Oncogene 1999 18 20 3063 3070 2-s2.0-0033587084 10.1038/sj.onc.1202893 (Pubitemid 29261226)
37. Krappmann D., Emmerich F., Kordes U., Scharschmidt E., Dörken B., Scheidereit C., Molecular mechanisms of constitutive NF- κ B/Rel activation in Hodgkin/Reed-Sternberg cells. Oncogene 1999 18 4 943 953 2-s2.0-0033611588 10.1038/sj.onc.1202351 (Pubitemid 29086271)
38. Jungnickel B., Staratschek-Jox A., Bräuninger A., Spieker T., Wolf J., Diehl V., Hansmann M. L., Rajewsky K., Küppers R., Clonal deleterious mutations in the i κ b α gene in the malignant cells in Hodgkin's lymphoma. Journal of Experimental Medicine 2000 191 2 395 402 2-s2.0-0034677104 10.1084/jem.191.2.395 (Pubitemid 30060929)
39. Emmerich F., Theurich S., Hummel M., Haeffker A., Vry M. S., Döhner K., Bommert K., Stein H., Dörken B., Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. Journal of Pathology 2003 201 3 413 420 2-s2.0-0242391871 10.1002/path.1454 (Pubitemid 37408262)
40. Emmerich F., Meiser M., Hummel M., Demel G., Foss H. D., Jundt F., Mathas S., Krappmann D., Scheidereit C., Stein H., Dörken B., Overexpression of I kappa B alpha without inhibition of NF- κ B activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 1999 94 9 3129 3134 2-s2.0-0033230955 (Pubitemid 29512720)
41. Takacs M., Segesdi J., Banati F., The importance of epigenetic alterations in the development of epstein-barr virus-related lymphomas. Mediterranean Journal of Hematology and Infectious Diseases 2009 1 2 e2009012
42. Carbone A., Spina M., Gloghini A., Tirelli U., Classical Hodgkin's lymphoma arising in different host's conditions: pathobiology parameters, therapeutic options, and outcome. American Journal of Hematology 2011 86 2 170 179 2-s2.0-78851472242 10.1002/ajh.21910
43. Serraino D., Boschini A., Carrieri P., Pradier C., Dorrucci M., Dal Maso L., Ballarini P., Pezzotti P., Smacchia C., Pesce A., Ippolito G., Franceschi S., Rezza G., Cancer risk among men with, or at risk of, HIV infection in southern Europe. AIDS 2000 14 5 553 559 2-s2.0-0034128301 10.1097/00002030- 200003310-00011 (Pubitemid 30209698)
44. Franceschi S., Dal Maso L., Pezzotti P., Polesel J., Braga C., Piselli P., Serraino D., Tagliabue G., Federico M., Ferretti S., De Lisi V., La Rosa F., Conti E., Budroni M., Vicario G., Piffer S., Pannelli F., Giacomin A., Bellù F., Tumino R., Fusco M., Rezza G., Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 19861998. Journal of Acquired Immune Deficiency Syndromes 2003 34 1 84 90 2-s2.0-0041412821 10.1097/00126334-200309010-00013 (Pubitemid 37100117)
45. Clifford G. M., Rickenbach M., Lise M., Dal Maso L., Battegay M., Bohlius J., El Amari E. B., Karrer U., Jundt G., Bordoni A., Ess S., Franceschi S., Hodgkin lymphoma in the Swiss HIV Cohort Study. Blood 2009 113 23 5737 5742 2-s2.0-67651121934 10.1182/blood-2009-02-204172
46. Grogg K. L., Miller R. F., Dogan A., HIV infection and lymphoma. Journal of Clinical Pathology 2007 60 12 1365 1372 2-s2.0-37048999551 10.1136/jcp.2007.051953 (Pubitemid 350247252)
47. Carbone A., Gloghini A., Serraino D., Spina M., HIV-associated Hodgkin lymphoma. Current Opinion in HIV and AIDS 2009 4 1 3 10 2-s2.0-67849135601 10.1097/COH.0b013e32831a722b
48. Tirelli U., Errante D., Dolcetti R., Gloghini A., Serraino D., Vaccher E., Franceschi S., Boiocchi M., Carbone A., Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. Journal of Clinical Oncology 1995 13 7 1758 1767 2-s2.0-0029061791
49. Vaccher E., Spina M., Talamini R., Zanetti M., Di Gennaro G., Nasti G., Tavio M., Bernardi D., Simonelli C., Tirelli U., Improvement of systemic human immunodeficiency virus-related non-hodgkin lymphoma outcome in the era of highly active antiretroviral therapy. Clinical Infectious Diseases 2003 37 11 1556 1564 2-s2.0-0344256604 10.1086/379517 (Pubitemid 37494686)
50. Chimienti E., Spina M., Gastaldi R., Clinical characteristics and outcome of 290 patients (pts) with Hodgkin's disease and HIV infection (HD-HIV) in pre and HAART (highly active antiretroviral therapy) era. Annals of Oncology 2008 9 136
51. Krishnan A., Molina A., Zaia J., Smith D., Vasquez D., Kogut N., Falk P. M., Rosenthal J., Alvarnas J., Forman S. J., Durable remissions with autologous stem cell transplantation for high-risk HTV-associated lymphomas. Blood 2005 105 2 874 878 2-s2.0-19944428843 10.1182/blood-2004-04-1532 (Pubitemid 40070778)
52. Serrano D., Carrión R., Balsalobre P., Miralles P., Berenguer J., Buo I., Gómez-Pineda A., Ribera J. M., Conde E., Díez- Martín J. L., HIV-associated lymphoma successfully treated with peripheral blood stem cell transplantation. Experimental Hematology 2005 33 4 487 494 2-s2.0-20144368090 10.1016/j.exphem.2004.12.008 (Pubitemid 40387632)
53. Re A., Michieli M., Casari S., Allione B., Cattaneo C., Rupolo M., Spina M., Manuele R., Vaccher E., Mazzucato M., Abbruzzese L., Ferremi P., Carosi G., Tirelli U., Rossi G., High-dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for AIDS-related lymphoma: long-term results of the Italian Cooperative Group on AIDS and Tumors (GICAT) study with analysis of prognostic factors. Blood 2009 114 7 1306 1313 2-s2.0-70349328418 10.1182/blood-2009-02-202762
54. Hayashi R. J., Kraus M. D., Patel A. L., Canter C., Cohen A. H., Hmiel P., Howard T., Huddleston C., Lowell J. A., Mallory G., Mendeloff E., Molleston J., Sweet S., DeBaun M. R., Posttransplant lymphoproliferative disease in children: correlation of histology to clinical behavior. Journal of Pediatric Hematology/Oncology 2001 23 1 14 18 2-s2.0-0035153094 10.1097/00043426- 200101000-00005 (Pubitemid 32124979)
55. Midthun D. E., Mcüougall J. C., Peters S. G., Scott J. P., Medical management and complications in the lung transplant recipient. Mayo Clinic Proceedings 1997 72 2 175 184 2-s2.0-0031419223 (Pubitemid 28201651)
56. Swerdlow S., Campo E., Harris N., Pathology and genetics of tumours of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumours, Lyon, France, IARC Press, 2008
57. Rohr J. C., Wagner H. J., Lauten M., Wacker H. H., Jüttner E., Hanke C., Pohl M., Niemeyer C. M., Differentiation of EBV-induced post-transplant Hodgkin lymphoma from Hodgkin-like post-transplant lymphoproliferative disease. Pediatric Transplantation 2008 12 4 426 431 2-s2.0-43249100043 10.1111/j.1399-3046.2007.00816.x (Pubitemid 351652070)
58. Knight J. S., Tsodikov A., Cibrik D. M., Ross C. W., Kaminski M. S., Blayney D. W., Lymphoma after solid organ transplantation: risk, response to therapy, and survival at a transplantation center. Journal of Clinical Oncology 2009 27 20 3354 3362 2-s2.0-70249127951 10.1200/JCO.2008.20.0857
59. Adams H., Campidelli C., Dirnhofer S., Pileri S. A., Tzankov A., Clinical, phenotypic and genetic similarities and disparities between post-transplant and classical Hodgkin lymphomas with respect to therapeutic targets. Expert Opinion on Therapeutic Targets 2009 13 10 1137 1145 2-s2.0-70349386193 10.1517/14728220903196779
60. Pham P. T. T., Wilkinson A. H., Gritsch H. A., Pham P. C. T., Miller J. M., Lassman C. R., Danovitch G. M., Monotherapy with the anti-CD20 monoclonal antibody rituximab in a kidney transplant recipient with posttransplant lymphoproliferative disease. Transplantation Proceedings 2002 34 4 1178 1181 2-s2.0-0035999009 10.1016/S0041-1345(02)02754-9 (Pubitemid 34665310)
61. Diehl V., Stein H., Hummel M., Zollinger R., Connors J. M., Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology 2003 225 247 2-s2.0-4544247638
62. Josting A., Nogová L., Franklin J., Glossmann J. P., Eich H. T., Sieber M., Schober T., Boettcher H. D., Schulz U., Müller R. P., Diehl V., Engert A., Salvage radiotherapy in patients with relapsed and refractory Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Lymphoma Study Group. Journal of Clinical Oncology 2005 23 7 1522 1529 2-s2.0-20144367598 10.1200/JCO.2005.05.022
63. Tzankov A., Krugmann J., Fend F., Fischhofer M., Greil R., Dirnhofer S., Prognostic significance of CD20 expression in classical Hodgkin lymphoma: a clinicopathological study of 119 cases. Clinical Cancer Research 2003 9 4 1381 1386 2-s2.0-0037390128 (Pubitemid 36418390)
64. Donnelly G., Filippa D., Moskowitz C., Increased treatment failure in patients with CD20 positive classic Hodgkin disease (HD). Blood 1999 94 598A
65. Rassidakis G. Z., Medeiros L. J., Viviani S., Bonfante V., Nadali G. P., Vassilakopoulos T. P., Mesina O., Herling M., Angelopoulou M. K., Giardini R., Chilosi M., Kittas C., McLaughlin P., Rodriguez M. A., Romaguera J., Bonadonna G., Gianni A. M., Pizzolo G., Pangalis G. A., Cabanillas F., Sarris A. H., CD20 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin's disease: associations with presenting features and clinical outcome. Journal of Clinical Oncology 2002 20 5 1278 1287 2-s2.0-0036498728 10.1200/JCO.20.5.1278 (Pubitemid 34177434)
66. Portlock C. S., Donnelly G. B., Qin J., Straus D., Yahalom J., Zelenetz A., Noy A., O'Connor O., Horwitz S., Moskowitz C., Filippa D. A., Adverse prognostic significance of CD20 positive Reed-Sternberg cells in classical Hodgkin's disease. British Journal of Haematology 2004 125 6 701 708 2-s2.0-3042638651 10.1111/j.1365-2141.2004.04964.x (Pubitemid 38813596)
67. Canioni D., Deau-Fischer B., Taupin P., Ribrag V., Delarue R., Bosq J., Rubio M. T., Roux D., Vasiliu V., Varet B., Brousse N., Hermine O., Prognostic significance of new immunohistochemical markers in refractory classical Hodgkin lymphoma: a study of 59 cases. PLoS ONE 2009 4 7 2-s2.0-67749106603 10.1371/journal.pone.0006341 e6341
68. Linch D. C., Winfield D., Goldstone A. H., Moir D., Hancock B., McMillan A., Chopra R., Milligan D., Vaughan Hudson G., Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. The Lancet 1993 341 8852 1051 1054 2-s2.0-0027404777 10.1016/0140-6736(93)92411-L (Pubitemid 23114397)
69. Schmitz N., Pfistner B., Sextro M., Sieber M., Carella A. M., Haenel M., Boissevain F., Zschaber R., Müller P., Kirchner H., Lohri A., Decker S., Koch B., Hasenclever D., Goldstone A. H., Diehl V., Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. The Lancet 2002 359 9323 2065 2071 2-s2.0-0037097044 10.1016/S0140-6736(02)08938-9 (Pubitemid 34680969)
70. Fozza C., Longinotti M., T-cell traffic jam in Hodgkin's lymphoma: pathogenetic and therapeutic implications. Advances in Hematology 2011 2011 8 2-s2.0-78349290436 10.1155/2011/501659 501659
71. Küppers R., Molecular biology of Hodgkin lymphoma. Hematology 2009 2009 1 491 496 2-s2.0-77949426782
72. Atkinson E. A., Bleackley R. C., Mechanisms of lysis by cytotoxic T cells. Critical Reviews in Immunology 1995 15 3-4 359 384 2-s2.0-0029521162 (Pubitemid 26259136)
73. Berke G., The CTL's kiss of death. Cell 1995 81 1 9 12 2-s2.0-0028932731
74. de Visser K. E., Kast W. M., Effects of TGF- β on the immune system: implications for cancer immunotherapy. Leukemia 1999 13 8 1188 1199 2-s2.0-0032868805 (Pubitemid 29396578)
75. Bladergroen B. A., Meijer C. J. L. M., Ten Berge R. L., Hack C. E., Muris J. J. F., Dukers D. F., Chott A., Kazama Y., Oudejans J. J., Van Berkum O., Kummer J. A., Expression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system? Blood 2002 99 1 232 237 2-s2.0-0036095702 10.1182/blood.V99.1.232 (Pubitemid 34532988)
76. Poppema S., Potters M., Emmens R., Visser L., van den Berg A., Immune reactions in classical Hodgkin's lymphoma. Seminars in Hematology 1999 36 3 253 259 2-s2.0-0032813515 (Pubitemid 29360217)
77. Kosmaczewska A., Frydecka I., Boćko D., Ciszak L., Teodorowska R., Correlation of blood lymphocyte CTLA-4 (CD152) induction in Hodgkin's disease with proliferative activity, interleukin 2 and interferon-gamma production. British Journal of Haematology 2002 118 1 202 209 2-s2.0-0036069288 10.1046/j.1365-2141.2002.03572.x (Pubitemid 34779538)
78. Su C. C., Chiu H. H., Chang C. C., Chen J. C., Hsu S. M., CD30 Is Involved in Inhibition of T-Cell Proliferation by Hodgkin's Reed-Sternberg Cells. Cancer Research 2004 64 6 2148 2152 2-s2.0-1542615073 10.1158/0008-5472.CAN-03-1337 (Pubitemid 38339466)
79. Teofili L., Di Febo A. L., Pierconti F., Maggiano N., Bendandi M., Rutella S., Cingolani A., Di Renzo N., Musto P., Pileri S., Leone G., Larocca L. M., Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. Blood 2001 97 4 1063 1069 2-s2.0-0035865510 10.1182/blood.V97.4.1063 (Pubitemid 32154294)
80. Reis L., Melbert D., Krapcho M., SEER Cancer Statistics Review, 19752005 2008 Bethesda, Md, USA National Cancer Institute
81. Goodell M. A., Brose K., Paradis G., Conner A. S., Mulligan R. C., Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. Journal of Experimental Medicine 1996 183 4 1797 1806 2-s2.0-0029958876 10.1084/jem.183.4.1797 (Pubitemid 26134320)
82. Goodell M. A., Rosenzweig M., Kim H., Marks D. F., Demaria M., Paradis G., Grupp S. A., Sieff C. A., Mulligan R. C., Johnson R. P., Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nature Medicine 1997 3 12 1337 1345 2-s2.0-0031435428 10.1038/nm1297-1337 (Pubitemid 28011033)
83. Hirschmann-Jax C., Foster A. E., Wulf G. G., Nuchtern J. G., Jax T. W., Gobel U., Goodell M. A., Brenner M. K., A distinct side population of cells with high drug efflux capacity in human tumor cells. Proceedings of the National Academy of Sciences of the United States of America 2004 101 39 14228 14233 2-s2.0-4644306516 10.1073/pnas.0400067101 (Pubitemid 39305058)
84. - cancer cells are similarly tumorigenic. Cancer Research 2005 65 14 6207 6219 2-s2.0-22244433866 10.1158/0008-5472.CAN-05-0592 (Pubitemid 40994406)
85. Moshaver B., Van Rhenen A., Kelder A., Van Der Pol M., Terwijn M., Bachas C., Westra A. H., Ossenkoppele G. J., Zweegman S., Schuurhuis G. J., Identification of a small subpopulation of candidate leukemia-initiating cells in the side population of patients with acute myeloid leukemia. Stem Cells 2008 26 12 3059 3067 2-s2.0-58049211689 10.1634/stemcells.2007-0861
86. Ho M. M., Ng A. V., Lam S., Hung J. Y., Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Research 2007 67 10 4827 4833 2-s2.0-34250306257 10.1158/0008-5472.CAN-06-3557 (Pubitemid 46910191)
87. Bunting K. D., ABC transporters as phenotypic markers and functional regulators of stem cells. Stem Cells 2002 20 1 11 20 2-s2.0-0036163796 (Pubitemid 34118906)
88. Zhou S., Schuetz J. D., Bunting K. D., Colapietro A. M., Sampath J., Morris J. J., Lagutina I., Grosveld G. C., Osawa M., Nakauchi H., Sorrentino B. P., The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nature Medicine 2001 7 9 1028 1034 2-s2.0-0034795256 10.1038/nm0901-1028 (Pubitemid 32937383)
89. Austin Doyle L., Yang W., Abruzzo L. V., Krogmann T., Gao Y., Rishi A. K., Ross D. D., A multidrug resistance transporter from human MCF-7 breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America 1998 95 26 15665 15670 2-s2.0-13044249156 10.1073/pnas.95.26. 15665 (Pubitemid 29018757)
90. Plasschaert S. L. A., de Bont E. S. J. M., Boezen M., Vander Kolk D. M., Daenen S. M. J. G., Faber K. N., Kamps W. A., De Vries E. G. E., Vellenga E., Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clinical Cancer Research 2005 11 24 8661 8668 2-s2.0-29344440700 10.1158/1078-0432.CCR-05-1096 (Pubitemid 43005914)
91. Shafer J. A., Cruz C. R., Leen A. M., Ku S., Lu A., Rousseau A., Heslop H. E., Rooney C. M., Bollard C. M., Foster A. E., Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphoma. Leukemia and Lymphoma 2010 51 5 870 880 2-s2.0-77951869394 10.3109/10428191003713968
92. Steidl C., Shah S. P., Woolcock B. W., Rui L., Kawahara M., Farinha P., Johnson N. A., Zhao Y., Telenius A., Neriah S. B., McPherson A., Meissner B., Okoye U. C., Diepstra A., Van Den Berg A., Sun M., Leung G., Jones S. J., Connors J. M., Huntsman D. G., Savage K. J., Rimsza L. M., Horsman D. E., Staudt L. M., Steidl U., Marra M. A., Gascoyne R. D., MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011 471 7338 377 383 2-s2.0-79952816655 10.1038/nature09754
93. Muenst S., Hoeller S., Dirnhofer S., Tzankov A., Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Human Pathology 2009 40 12 1715 1722 2-s2.0-70349408300 10.1016/j.humpath.2009.03.025
94. Curiel T. J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J. R., Zhang L., Burow M., Zhu Y., Wei S., Kryczek I., Daniel B., Gordon A., Myers L., Lackner A., Disis M. L., Knutson K. L., Chen L., Zou W., Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nature Medicine 2004 10 9 942 949 2-s2.0-4644237613 10.1038/nm1093 (Pubitemid 39273735)
95. + regulatory T cells. Nature Immunology 2003 4 4 330 336 2-s2.0-0037385330 10.1038/ni904 (Pubitemid 36432314)
96. + T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. Journal of Immunology 1998 160 3 1212 1218 2-s2.0-0031939403 (Pubitemid 28093417)
97. + regulatory T cells in the human immune system. Nature Reviews Immunology 2010 10 7 490 500 2-s2.0-77954141914 10.1038/nri2785
98. + regulatory T cells through GITR breaks immunological self-tolerance. Nature Immunology 2002 3 2 135 142 2-s2.0-0036170938 10.1038/ni759 (Pubitemid 34141443)
99. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. Journal of Experimental Medicine 2001 194 6 823 832 2-s2.0-0035903324 10.1084/jem.194.6.823 (Pubitemid 32983017)
100. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. Journal of Experimental Medicine 2000 192 2 303 309 2-s2.0-0034679560 10.1084/jem.192.2.303 (Pubitemid 30470313)
101. + regulatory T cells, in adult T-cell leukaemia/lymphoma cells. British Journal of Haematology 2004 126 1 81 84 2-s2.0-3042838753 10.1111/j.1365-2141.2004.04999.x (Pubitemid 38859486)
102. Hori S., Nomura T., Sakaguchi S., Control of regulatory T cell development by the transcription factor Foxp3. Science 2003 299 5609 1057 1061 2-s2.0-0347785480 10.1126/science.1079490 (Pubitemid 36222930)
103. Teichmann M., Meyer B., Beck A., Niedobitek G., Expression of the interferon-inducible chemokine IP-10 (CXCL10), a chemokine with proposed anti-neoplastic functions, in Hodgkin lymphoma and nasopharyngeal carcinoma. Journal of Pathology 2005 206 1 68 75 2-s2.0-18144392742 10.1002/path.1745 (Pubitemid 40613436)
104. + regulatory T cells suppress NKT cell functions. Cancer Research 2003 63 15 4516 4520 2-s2.0-0041589414 (Pubitemid 36951023)
105. Wolf A. M., Wolf D., Steurer M., Gastl G., Gunsilius E., Grubeck-Loebenstein B., Increase of regulatory T cells in the peripheral blood of cancer patients. Clinical Cancer Research 2003 9 2 606 612 2-s2.0-0037312480 (Pubitemid 36182591)
106. Yamaguchi T., Sakaguchi S., Regulatory T cells in immune surveillance and treatment of cancer. Seminars in Cancer Biology 2006 16 2 115 123 2-s2.0-31644432589 10.1016/j.semcancer.2005.11.005 (Pubitemid 43172060)
107. Wang H. Y., Wang R. F., Regulatory T cells and cancer. Current Opinion in Immunology 2007 19 2 217 223 (Pubitemid 46356965)
108. Ostrand-Rosenberg S., Sinha P., Myeloid-derived suppressor cells: linking inflammation and cancer. Journal of Immunology 2009 182 8 4499 4506 2-s2.0-65249138393 10.4049/jimmunol.0802740
109. Movahedi K., Laoui D., Gysemans C., Baeten M., Stangé G., Van Bossche J. D., Mack M., Pipeleers D., In't Veld P., De Baetselier P., Van Ginderachter J. A., Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C(high) monocytes. Cancer Research 2010 70 14 5728 5739 2-s2.0-77955038532 10.1158/0008-5472.CAN-09-4672
110. Zamarron B. F., Chen W., Dual roles of immune cells and their factors in cancer development and progression. International Journal of Biological Sciences 2011 7 5 651 658 2-s2.0-79960122931
111. Biswas S. K., Mantovani A., Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunology 2010 11 10 889 896 2-s2.0-77956976681 10.1038/ni.1937
112. Khramtsova G., Liao C., Khramtsov A., The M2/alternatively activated macrophage phenotype correlates with aggressive histopathologic features and poor clinical outcome in early stage breast cancer. Cancer Research 2009 69 24, supplement, abstract 107
113. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A., Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends in Immunology 2002 23 11 549 555 2-s2.0-0036839143 10.1016/S1471-4906(02)02302-5 (Pubitemid 35223554)
114. Pollard J. W., Tumour-educated macrophages promote tumour progression and metastasis. Nature Reviews Cancer 2004 4 1 71 78 2-s2.0-0347123433 (Pubitemid 38082155)
115. Talmadge J. E., Donkor M., Scholar E., Inflammatory cell infiltration of tumors: jekyll or Hyde. Cancer and Metastasis Reviews 2007 26 3-4 373 400 2-s2.0-36148960830 10.1007/s10555-007-9072-0 (Pubitemid 350115102)
116. Bingle L., Brown N. J., Lewis C. E., The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. Journal of Pathology 2002 196 3 254 265 2-s2.0-0036187615 10.1002/path.1027 (Pubitemid 34189413)
117. Condeelis J., Pollard J. W., Macrophages: obligate partners for tumor
118. Mantovani A., Allavena P., Sica A., Tumour-associated macrophages as a prototypic type II polarised phagocyte population: role in tumour progression. European Journal of Cancer 2004 40 11 1660 1667 2-s2.0-3142644996 10.1016/j.ejca.2004.03.016 (Pubitemid 38902900)
119. Pollard J. W., Macrophages define the invasive microenvironment in breast cancer. Journal of Leukocyte Biology 2008 84 3 623 630 2-s2.0-50849090319 10.1189/jlb.1107762
120. Clark C. E., Hingorani S. R., Mick R., Combs C., Tuveson D. A., Vonderheide R. H., Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Research 2007 67 19 9518 9527 2-s2.0-35148814410 10.1158/0008-5472.CAN-07-0175 (Pubitemid 47535942)
121. Dave S. S., Wright G., Tan B., Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. The New England Journal of Medicine 2004 351 21 2159 2169 (Pubitemid 39507628)
122. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F. L., Walker M. G., Watson D., Park T., Hiller W., Fisher E. R., Wickerham D. L., Bryant J., Wolmark N., A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. The New England Journal of Medicine 2004 351 27 2817 2826 2-s2.0-19944422061 10.1056/NEJMoa041588 (Pubitemid 40051905)
123. Taskinen M., Karjalainen-Lindsberg M. L., Nyman H., Eerola L. M., Leppä S., A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide- doxorubicin-vincristine-prednisone. Clinical Cancer Research 2007 13 19 5784 5789 2-s2.0-35348843627 10.1158/1078-0432.CCR-07-0778 (Pubitemid 47591642)
124. Steidl C., Lee T., Shah S. P., Farinha P., Han G., Nayar T., Delaney A., Jones S. J., Iqbal J., Weisenburger D. D., Bast M. A., Rosenwald A., Muller-Hermelink H. K., Rimsza L. M., Campo E., Delabie J., Braziel R. M., Cook J. R., Tubbs R. R., Jaffe E. S., Lenz G., Connors J. M., Staudt L. M., Chan W. C., Gascoyne R. D., Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. The New England Journal of Medicine 2010 362 10 875 885 2-s2.0-77949345555 10.1056/NEJMoa0905680
125. Birgersdotter A., Baumforth K. R. N., Porwit A., Sjöberg J., Wei W., Björkholm M., Murray P. G., Ernberg I., Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma. British Journal of Cancer 2009 101 8 1393 1401 2-s2.0-70349973447 10.1038/sj.bjc.6605238
126. Poppema S., Visser L., Absence of HLA class I expression by Reed-Sternberg cells. American Journal of Pathology 1994 145 1 37 41 2-s2.0-0028363221 (Pubitemid 24217480)
127. Newcom S. R., Kadin M. E., Ansari A. A., Diehl V., L-428 nodular sclerosing Hodgkin's cell secretes a unique transforming growth factor-beta active at physiologic pH. Journal of Clinical Investigation 1988 82 6 1915 1921 2-s2.0-0024210873 (Pubitemid 19054938)
128. + T lymphocytes. International Journal of Cancer 1995 62 1 5 10 2-s2.0-0029075448 10.1002/ijc.2910620103
129. Medema J. P., de Jong J., Peltenburg L. T. C., Verdegaal E. M. E., Gorter A., Bres S. A., Franken K. L. M. C., Hahne M., Albar J. P., Melief C. J. M., Offringa R., Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proceedings of the National Academy of Sciences of the United States of America 2001 98 20 11515 11520 2-s2.0-0035949570 10.1073/pnas. 201398198 (Pubitemid 32928760)
130. + T-cell function in Hodgkin lymphoma patients. Blood 2006 108 7 2280 2289 2-s2.0-33749127585 10.1182/blood-2006-04- 015164 (Pubitemid 44497511)
131. Marshall N. A., Vickers M. A., Barker R. N., Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. Journal of Immunology 2003 170 12 6183 6189 2-s2.0-0038280092 (Pubitemid 36682602)
132. + T cell responses. Journal of Experimental Medicine 2003 198 6 889 901 2-s2.0-0141449974 10.1084/jem.20030171 (Pubitemid 37152926)
133. Huard B., Mastrangeli R., Prigent P., Bruniquel D., Donini S., El-Tayar N., Maigret B., Dréano M., Triebel F., Characterization of the major histocompatibility complex class II binding site on LAG-3 protein. Proceedings of the National Academy of Sciences of the United States of America 1997 94 11 5744 5749 2-s2.0-0030902983 10.1073/pnas.94.11.5744 (Pubitemid 27241841)
134. Hannier S., Tournier M., Bismuth G., Triebel F., CD3/TCR complex-associated lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. Journal of Immunology 1998 161 8 4058 4065 2-s2.0-0032532284 (Pubitemid 28468984)
135. Maon-Lemaître L., Triebel F., The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology 2005 115 2 170 178 2-s2.0-19544374904 10.1111/j.1365-2567.2005.02145. x (Pubitemid 40733402)
136. Meng Y., Beckett M. A., Liang H., Mauceri H. J., Van Rooijen N., Cohen K. S., Weichselbaum R. R., Blockade of tumor necrosis factor α signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Research 2010 70 4 1534 1543 2-s2.0-76749106110 10.1158/0008-5472.CAN-09-2995
137. Ahn G. O., Tseng D., Liao C. H., Dorie M. J., Czechowicz A., Brown J. M., Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proceedings of the National Academy of Sciences of the United States of America 2010 107 18 8363 8368 2-s2.0-77952389941 10.1073/pnas.0911378107
138. Molin D., Fischer M., Xiang Z., Larsson U., Harvima I., Venge P., Nilsson K., Sundström C., Enblad G., Nilsson G., Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. British Journal of Haematology 2001 114 3 616 623 2-s2.0-0034796923 10.1046/j.1365-2141.2001.02977.x (Pubitemid 32953640)
139. Pagès F., Galon J., Dieu-Nosjean M. C., Tartour E., Sautès-Fridman C., Fridman W. H., Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 2010 29 8 1093 1102 2-s2.0-77649193013 10.1038/onc.2009.416
140. + Hodgkin's disease. Journal of Experimental Medicine 2004 200 12 1623 1633 2-s2.0-19944426160 10.1084/jem.20040890 (Pubitemid 40094186)
141. Alvaro T., Lejeune M., Escriva P., Appraisal of immune response in lymphoproliferative syndromes: a systematic review. Critical Reviews in Oncology/Hematology 2009 70 2 103 113
142. Diehl V., Thomas R. K., Re D., Part II: Hodgkin's lymphomadiagnosis and treatment. Lancet Oncology 2004 5 1 19 26 2-s2.0-0347286860 10.1016/S1470- 2045(03)01320-2 (Pubitemid 38072556)
143. Connors J. M., State-of-the-art therapeutics: Hodgkin's lymphoma. Journal of Clinical Oncology 2005 23 26 6400 6408 2-s2.0-27244442106 10.1200/JCO.2005.05.016 (Pubitemid 46222240)
144. Specht L., Hasenclever D., Prognostic factors of Hodgkin's disease. Hodgkin's Disease 1999 Philadelphia, Pa, USA Lippincott Williams & Wilkins 295 325
145. Engert A., Plutschow A., Eich H. T., Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. The New England Journal of Medicine 2010 363 7 640 652
146. Hasenclever D., Diehl V., A prognostic score for advanced Hodgkin's disease. The New England Journal of Medicine 1998 339 21 1506 1514 2-s2.0-0032548107 10.1056/NEJM199811193392104 (Pubitemid 28543499)
147. + T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. Journal of Clinical Oncology 2001 19 3 720 726 2-s2.0-0035253726 (Pubitemid 32119086)
148. + T cells in Hodgkin's disease tumor tissue are a polyclonal population with limited clonal expansion but little evidence of selection by antigen. American Journal of Pathology 2000 157 1 171 175 2-s2.0-0033882631 (Pubitemid 30641734)
149. Sanchez-Espiridion B., Montalban C., Lopez A., A molecular risk score based on 4 functional pathways for advanced classical Hodgkin lymphoma. Blood 2010 116 8 e12 e17
150. Bosshart H., Ansell S. M., Jelinek D. F., Wettstein P. J., Witzig T. E., T helper cell activation in B-cell lymphomas. Journal of Clinical Oncology 2002 20 12 2904 2905 2-s2.0-0037096936
151. Kanavaros P., Vlychou M., Stefanaki K., Rontogianni D., Gaulard P., Pantelidaki E., Zois M., Darivianaki K., Georgoulias V., Boulland M. L., Gorgoulis V., Kittas C., Cytotoxic protein expression in non-Hodgkin's lymphomas and Hodgkin's disease. Anticancer Research A 1999 19 2 1209 1216 2-s2.0-0032994029 (Pubitemid 29257560)
152. ten Berge R. L., Oudejans J. J., Dukers D. F., Meijer J. W. R., Ossenkoppele G. J., Meijer C. J. L. M., Percentage of activated cytotoxic T-lymphocytes in anaplastic large cell lymphoma and Hodgkin's disease: an independent biological prognostic marker. Leukemia 2001 15 3 458 464 2-s2.0-0035084021 10.1038/sj.leu.2402045 (Pubitemid 32243781)
153. Camilleri-Broët S., Fermé C., Berger F., Lepage E., Bain S., Brière J., Marmey B., Gaulard P., Audouin J., TiA1 in advanced-stage classical Hodgkin's lymphoma: no prognostic impact for positive tumour cells or number of cytotoxic cells. Virchows Archiv 2004 445 4 344 346 2-s2.0-8744289517 10.1007/s00428-004-1057-6 (Pubitemid 39517758)
154. Kamper P., Bendix K., Hamilton-Dutoit S., Honoré B., Nyengaard J. R., D'Amore F., Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma. Haematologica 2011 96 2 269 276 2-s2.0-79551650002 10.3324/haematol.2010.031542
155. Leoncini L., Spina D., Megha T., Gallorini M., Tosi P., Hummel M., Stein H., Pileri S., Kraft R., Laissue J. A., Cottier H., Cell kinetics, morphology, and molecular IgV(H) gene rearrangements in Hodgkin's disease. Leukemia and Lymphoma 1997 26 3-4 307 316 2-s2.0-9844219744 (Pubitemid 27401914)
156. Bargou R. C., Emmerich F., Krappmann D., Bommert K., Mapara M. Y., Arnold W., Royer H. D., Grinstein E., Greiner A., Scheidereit C., Dörken B., Constitutive nuclear factor- κ b-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. Journal of Clinical Investigation 1997 100 12 2961 2969 2-s2.0-18844465632 (Pubitemid 28022832)
157. Hinz M., Lemke P., Anagnostopoulos I., Hacker C., Krappmann D., Mathas S., Dörken B., Zenke M., Stein H., Scheidereit C., Nuclear factor κ b-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. Journal of Experimental Medicine 2002 196 5 605 617 2-s2.0-0036707512 10.1084/jem.20020062 (Pubitemid 35024439)
158. Hinz M., Löser P., Mathas S., Krappmann D., Dörken B., Scheidereit C., Constitutive NF- κ B maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 2001 97 9 2798 2807 2-s2.0-0035324928 10.1182/blood.V97.9.2798
159. Izban K. F., Ergin M., Huang Q., Qin J. Z., Martinez R. L., Schnitzer B., Ni H., Nickoloff B. J., Alkan S., Characterization of NF- κ B expression in Hodgkin's disease: inhibition of constitutively expressed NF- κ B results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. Modern Pathology 2001 14 4 297 310 2-s2.0-0034744586 10.1038/modpathol.3880306 (Pubitemid 32298915)
160. Mathas S., Hinz M., Anagnostopoulos I., Krappmann D., Lietz A., Jundt F., Bommert K., Mechta-Grigoriou F., Stein H., Dörken B., Scheidereit C., Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF- κ B. The EMBO Journal 2002 21 15 4104 4113 2-s2.0-18444369000 10.1093/emboj/cdf389 (Pubitemid 34857442)
161. Sanchez-Beato M., Piris M. A., Martinez-Montero J. C., MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease. The Journal of Pathology 1996 180 1 58 64 (Pubitemid 26348892)
162. Küpper M., Joos S., von Bonin F., Daus H., Pfreundschuh M., Lichter P., Trümper L., MDM2 gene amplification and lack of p53 point mutations in Hodgkin and Reed-Sternberg cells: results from single-cell polymerase chain reaction and molecular cytogenetic studies. British Journal of Haematology 2001 112 3 768 775 2-s2.0-0035100156 10.1046/j.1365-2141.2001.02566.x (Pubitemid 32222851)
163. Morente M. M., Piris M. A., Abraira V., Acevedo A., Aguilera B., Bellas C., Fraga M., Garcia-Del-Moral R., Gomez-Marcos F., Menarguez J., Oliva H., Sanchez-Beato M., Montalban C., Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki67 proliferation index, and absence of Epstein-Barr Virus-latent membrane protein 1 expression. Blood 1997 90 6 2429 2436 2-s2.0-0030801898 (Pubitemid 27392727)
164. Montesinos-Rongen M., Roers A., Küppers R., Rajewsky K., Hansmann M. L., Mutation of the p53 gene is not a typical feature of Hodgkin and Reed- Sternberg cells in Hodgkin's disease. Blood 1999 94 5 1755 1760 2-s2.0-0033199296 (Pubitemid 29411326)
165. García J. F., Villuendas R., Algara P., Sáez A. I., Sánchez-Verde L., Martínez-Montero J. C., Martínez P., Piris M. A., Loss of p16 protein expression associated with methylation of the p16(INK4A) gene is a frequent finding in Hodgkin's disease. Laboratory Investigation 1999 79 12 1453 1459 2-s2.0-0033391985 (Pubitemid 30013910)
166. Montalbán C., García J. F., Abraira V., González-Camacho L., Morente M. M., Bello J. L., Conde E., Cruz M. A., García-Sanz R., García-Laraa J., Grande C., Llanos M., Martĩnez R., Flores E., Méndez M., Ponderós C., Rayón C., Sánchez-Godoy P., Zamora J., Piris M. A., Influence of biologic markers on the outcome of Hodgkin's lymphoma: a study by the Spanish Hodgkin's Lymphoma Study Group. Journal of Clinical Oncology 2004 22 9 1664 1673 2-s2.0-2442644270 10.1200/JCO.2004.06.105 (Pubitemid 41079805)
167. Rassidakis G. Z., Medeiros L. J., McDonnell T. J., Viviani S., Bonfante V., Nadali G., Vassilakopoulos T. P., Giardini R., Chilosi M., Kittas C., Gianni A. M., Bonadonna G., Pizzolo G., Pangalis G. A., Cabanillas F., Sarris A. H., BAX expression in Hodgkin and Reed-Sternberg cells of Hodgkin's disease: correlation with clinical outcome. Clinical Cancer Research 2002 8 2 488 493 2-s2.0-0036189683 (Pubitemid 34201758)
168. Rassidakis G. Z., Medeiros L. J., Vassilakopoulos T. P., Viviani S., Bonfante V., Nadali G., Herling M., Angelopoulou M. K., Giardini R., Chilosi M., Kittas C., McDonnell T. J., Bonadonna G., Gianni A. M., Pizzolo G., Pangalis G. A., Cabanillas F., Sarris A. H., BCL-2 expression in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease predicts a poorer prognosis in patients treated with ABVD or equivalent regimens. Blood 2002 100 12 3935 3941 2-s2.0-0036892729 10.1182/blood.V100.12.3935 (Pubitemid 35396858)
169. Sup S. J., Alemay C. A., Pohlman B., Elson P., Malhi S., Thakkar S., Steinle R., Hsi E. D., Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome. Journal of Clinical Oncology 2005 23 16 3773 3779 2-s2.0-20544445939 10.1200/JCO.2005.04.358
170. Brink A. A. T. P., Oudejans J. J., van den Brule A. J. C., Kluin P. M., Horstman A., Ossenkoppele G. J., Van Heerde P., Jiwa M., Meijer C. J. L. M., Low p53 and high bcl-2 expression in Reed-Sternberg cells predicts poor clinical outcome for Hodgkin's disease: involvement of apoptosis resistance? Modern Pathology 1998 11 4 376 383 2-s2.0-0031978387 (Pubitemid 28208101)
171. Garcia J. F., Camacho F. I., Morente M., Fraga M., Montalbán C., Álvaro T., Bellas C., Castao Á.., Díez A., Flores T., Martín C., Martínez M. A., Mazorra F., Menárguez J., Mestre M. J., Mollejo M., Sáez A. I., Sánchez L., Piris M. A., Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays. Blood 2003 101 2 681 689 2-s2.0-0037438584 10.1182/blood-2002-04-1128 (Pubitemid 36077593)
172. Smolewski P., Robak T., Krykowski E., Blasiska-Morawiec M., Niewiadomska H., Pluzanska A., Chmielowska E., Zambrano O., Prognostic factors in Hodgkin's disease: multivariate analysis of 327 patients from a single institution. Clinical Cancer Research 2000 6 3 1150 1160 2-s2.0-0034103158 (Pubitemid 30159379)
173. Abele M. C., Valente G., Kerim S., Navone R., Onesti P., Chiusa L., Resegotti L., Palestro G., Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin's disease: an immunohistochemical study with Ki67 and MIB-1 monoclonal antibodies. Haematologica 1997 82 3 281 285 2-s2.0-0031438386 (Pubitemid 28023301)
174. Bai M., Papoudou-Bai A., Kitsoulis P., Horianopoulos N., Kamina S., Agnantis N. J., Kanavaros P., Cell cycle and apoptosis deregulation in classical Hodgkin lymphomas. In Vivo 2005 19 2 439 454 2-s2.0-16344384883 (Pubitemid 40467631)
175. Devilard E., Bertucci F., Trempat P., Bouabdallah R., Loriod B., Giaconia A., Brousset P., Granjeaud S., Nguyen C., Birnbaum D., Birg F., Houlgatte R., Xerri L., Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene 2002 21 19 3095 3102 2-s2.0-18344374002 10.1038/sj/onc/1205418 (Pubitemid 34522911)
176. Famularo G., De Simone C., Tzantzoglou S., Trinchieri V., Apoptosis, anti-apoptotic compounds and TNF- α release. Immunology Today 1994 15 10 495 496 2-s2.0-0028004683 10.1016/0167-5699(94)90196-1 (Pubitemid 24316017)
177. Hahne M., Renno T., Schroeter M., Irmler M., French L., Bornand T., MacDonald H. R., Tschopp J., Activated B cells express functional Fas ligand. European Journal of Immunology 1996 26 3 721 724 2-s2.0-0029916079 10.1002/eji.1830260332 (Pubitemid 26091406)
178. Álvaro T., Lejeune M., García J. F., Salvadó M. T., López C., Bosch R., Jaén J., Escrivá P., Pons L. E., Tumor-infiltrated immune response correlates with alterations in the apoptotic and cell cycle pathways in Hodgkin and Reed-Sternberg cells. Clinical Cancer Research 2008 14 3 685 691 2-s2.0-38949101159 10.1158/1078-0432.CCR-07-1246 (Pubitemid 351231148)
179. Metkar S. S., Manna P. P., Anand M., Naresh K. N., Advani S. H., Nadkarni J. J., CD40 ligandan anti-apoptotic molecule in Hodgkin's disease. Cancer Biotherapy and Radiopharmaceuticals 2001 16 1 85 92 2-s2.0-0035085332 (Pubitemid 32231720)
180. Kater A. P., Evers L. M., Remmerswaal E. B. M., Jaspers A., Oosterwijk M. F., Van Lier R. A. W., Van Oers M. H. J., Eldering E., CD40 stimulation of B-cell chronic lymphocytic leukaemia cells enhances the anti-apoptotic profile, but also Bid expression and cells remain susceptible to autologous cytotoxic T-lymphocyte attack. British Journal of Haematology 2004 127 4 404 415 2-s2.0-8844226681 10.1111/j.1365-2141.2004.05225.x (Pubitemid 39536592)
181. Inoue J. I., Ishida T., Tsukamoto N., Kobayashi N., Naito A., Azuma S., Yamamoto T., Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Experimental Cell Research 2000 254 1 14 24 2-s2.0-0034627798 10.1006/excr.1999.4733 (Pubitemid 30066727)
182. Lee H. H., Dadgostar H., Cheng Q., Shu J., Cheng G., NF- κ B-mediated up-regulation of Bcl-x and Bfl-1/A1 is required for CD40 survival signaling in B lymphocytes. Proceedings of the National Academy of Sciences of the United States of America 1999 96 16 9136 9141 2-s2.0-0033529416 10.1073/pnas.96.16.9136 (Pubitemid 29374720)
183. Hong S. Y., Yoon W. H., Park J. H., Kang S. G., Ahn J. H., Lee T. H., Involvement of two NF- κ B binding elements in tumor necrosis factor α -, CD40-, and Epstein-Barr virus latent membrane protein 1-mediated induction of the cellular inhibitor of apoptosis protein 2 gene. Journal of Biological Chemistry 2000 275 24 18022 18028 2-s2.0-0034674737 10.1074/jbc.M001202200 (Pubitemid 30414748)
184. Thome M., Tschopp J., Regulation of lymphocyte proliferation and death by flip. Nature Reviews Immunology 2001 1 1 50 58 2-s2.0-0035496099 (Pubitemid 33741975)
185. Malumbres M., Barbacid M., To cycle or not to cycle: a critical decision in cancer. Nature Reviews Cancer 2001 1 3 222 231 2-s2.0-0035754080 (Pubitemid 33741897)
186. Wagner E. F., Hieb M., Hanna N., Sharma S., A pivotal role of cyclin D3 and cyclin-dependent kinase inhibitor p27 in the regulation of IL-2-, IL-4-, or IL-10-mediated human B cell proliferation. Journal of Immunology 1998 161 3 1123 1131 2-s2.0-0032146276 (Pubitemid 28380536)
187. Blanchard D. A., Affredou M. T., Vazquez A., Modulation of the p27kip1 cyclin-dependent kinase inhibitor expression during IL-4-mediated human B cell activation 1. Journal of Immunology 1997 158 7 3054 3061 2-s2.0-0031111909 (Pubitemid 127484017)
188. + lymphocytes. Journal of Immunology 2005 174 5 2738 2745 2-s2.0-14044266906 (Pubitemid 40279689)
189. Shaffer A. L., Yu X., He Y., Boldrick J., Chan E. P., Staudt L. M., BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control. Immunity 2000 13 2 199 212 2-s2.0-0033680860
190. Tang T. T. L., Dowbenko D., Jackson A., Toney L., Lewin D. A., Dent A. L., Lasky L. A., The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor. Journal of Biological Chemistry 2002 277 16 14255 14265 2-s2.0-0037134491 10.1074/jbc.M110901200 (Pubitemid 34968040)
191. Calò V., Migliavacca M., Bazan V., Macaluso M., Buscemi M., Gebbia N., Russo A., STAT proteins: from normal control of cellular events to tumorigenesis. Journal of Cellular Physiology 2003 197 2 157 168 2-s2.0-0242285719 10.1002/jcp.10364 (Pubitemid 37485244)
192. Rudant J., Orsi L., Monnereau A., Childhood hodgkin's lymphoma, non-Hodgkin's lymphoma and factors related to the immune system: the Escale study (SFCE). International Journal of Cancer 2011 129 9 2236 2247 10.1002/ijc.25862
193. Khan G., Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? Experimental Hematology 2006 34 4 399 406 2-s2.0-33645227964 10.1016/j.exphem.2005.11.008
194. Kapatai G., Murray P., Contribution of the Epstein-Barr virus to the molecular pathogenesis of Hodgkin lymphoma. Journal of Clinical Pathology 2007 60 12 1342 1349 2-s2.0-37149031657 10.1136/jcp.2007.050146 (Pubitemid 350252944)
195. Jarrett R. F., Viruses and Hodgkin's lymphoma. Annals of Oncology 2002 13 1 23 29 2-s2.0-0036264762 10.1093/annonc/mdf047
196. Jarrett R. F., Viruses and lymphoma/leukaemia. Journal of Pathology 2006 208 2 176 186 2-s2.0-31144459051 10.1002/path.1905 (Pubitemid 43126111)
197. Lam N., Sugden B., CD40 and its viral mimic, LMP1: similar means to different ends. Cellular Signalling 2003 15 1 9 16 2-s2.0-0037209628 10.1016/S0898-6568(02)00083-9 (Pubitemid 35223624)
198. Kilger E., Kieser A., Baumann M., Hammerschmidt W., Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. The EMBO Journal 1998 17 6 1700 1709 2-s2.0-0032536860 10.1093/emboj/17.6.1700 (Pubitemid 28119123)
199. Young L. S., Rickinson A. B., Epstein-Barr virus: 40 years on. Nature Reviews Cancer 2004 4 10 757 768 2-s2.0-4944266319 10.1038/nrc1452 (Pubitemid 39331148)
200. Kennedy G., Komano J., Sugden B., Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proceedings of the National Academy of Sciences of the United States of America 2003 100 2 14269 14274 2-s2.0-0344630245 10.1073/pnas.2336099100 (Pubitemid 37499226)
201. Aldinucci D., Lorenzon D., Cattaruzza L., Pinto A., Gloghini A., Carbone A., Colombatti A., Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. International Journal of Cancer 2008 122 4 769 776 2-s2.0-38349059732 10.1002/ijc.23119
202. Fischer M., Juremalm M., Olsson N., Backlin C., Sundström C., Nilsson K., Enblad G., Nilsson G., Expression of CCL5/RANTES by Hodgkin and reed-sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. International Journal of Cancer 2003 107 2 197 201 2-s2.0-0141634201 10.1002/ijc.11370 (Pubitemid 37152897)
203. Hanamoto H., Nakayama T., Miyazato H., Takegawa S., Hieshima K., Tatsumi Y., Kanamaru A., Yoshie O., Expression of CCL28 by reed-sternberg cells defines a major subtype of classical Hodgkin's disease with frequent infiltration of eosinophils and/or plasma cells. American Journal of Pathology 2004 164 3 997 1006 2-s2.0-1242338864 (Pubitemid 38235481)
204. Baumforth K. R. N., Birgersdotter A., Reynolds G. M., Wei W., Kapatai G., Flavell J. R., Kalk E., Piper K., Lee S., Machado L., Hadley K., Sundblad A., Sjoberg J., Bjorkholm M., Porwit A. A., Yap L. F., Teo S., Grundy R. G., Young L. S., Ernberg I., Woodman C. B. J., Murray P. G., Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. American Journal of Pathology 2008 173 1 195 204 2-s2.0-46749136862 10.2353/ajpath.2008.070845 (Pubitemid 351947967)
205. Niens M., Visser L., Nolte I. M., Van Der Steege G., Diepstra A., Cordano P., Jarrett R. F., Te Meerman G. J., Poppema S., Van Den Berg A., Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. British Journal of Haematology 2008 140 5 527 536 2-s2.0-38949152337 10.1111/j.1365-2141.2007.06964.x (Pubitemid 351230079)
206. Chetaille B., Bertucci F., Finetti P., Esterni B., Stamatoullas A., Picquenot J. M., Copin M. C., Morschhauser F., Casasnovas O., Petrella T., Molina T., Vekhoff A., Feugier P., Bouabdallah R., Birnbaum D., Olive D., Xerri L., Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009 113 12 2765 2775 2-s2.0-63849185609 10.1182/blood-2008-07- 168096
207. Frisan T., Sjoberg J., Dolcetti R., Boiocchi M., De Re V., Carbone A., Brautbar C., Battat S., Biberfeld P., Eckman M., Ost A., Christensson B., Sundstrom C., Bjorkholm M., Pisa P., Masucci M. G., Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 1995 86 4 1493 1501 2-s2.0-0029087498
208. + cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin's lymphoma. Annals of Hematology 2005 84 10 661 666 2-s2.0-27644560606 10.1007/s00277-005-1051-3 (Pubitemid 41554242)
209. Ladoire S., Martin F., Ghiringhelli F., Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunology, Immunotherapy 2011 60 7 909 918 2-s2.0-79959742164 10.1007/s00262-011-1046-y
210. Marshall N. A., Culligan D. J., Tighe J., Johnston P. W., Barker R. N., Vickers M. A., The relationships between Epstein-Barr virus latent membrane protein 1 and regulatory T cells in Hodgkin's lymphoma. Experimental Hematology 2007 35 4 596 604 2-s2.0-33947275359 10.1016/j.exphem.2007.01.030 (Pubitemid 46427965)
211. Zitvogel L., Apetoh L., Ghiringhelli F., André F., Tesniere A., Kroemer G., The anticancer immune response: indispensable for therapeutic success? Journal of Clinical Investigation 2008 118 6 1991 2001 2-s2.0-45749134564 10.1172/JCI35180 (Pubitemid 351872317)
212. Casares N., Pequignot M. O., Tesniere A., Ghiringhelli F., Roux S., Chaput N., Schmitt E., Hamai A., Hervas-Stubbs S., Obeid M., Coutant F., Métivier D., Pichard E., Aucouturier P., Pierron G., Garrido C., Zitvogel L., Kroemer G., Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. Journal of Experimental Medicine 2005 202 12 1691 1701 2-s2.0-29144530630 10.1084/jem.20050915 (Pubitemid 41815875)
213. Nowak A. K., Robinson B. W. S., Lake R. A., Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Research 2003 63 15 4490 4496 2-s2.0-0042591416 (Pubitemid 36951021)
214. Haynes N. M., van der Most R. G., Lake R. A., Smyth M. J., Immunogenic anti-cancer chemotherapy as an emerging concept. Current Opinion in Immunology 2008 20 5 545 557 2-s2.0-50549088118 10.1016/j.coi.2008.05.008
215. Tesniere A., Apetoh L., Ghiringhelli F., Joza N., Panaretakis T., Kepp O., Schlemmer F., Zitvogel L., Kroemer G., Immunogenic cancer cell death: a key-lock paradigm. Current Opinion in Immunology 2008 20 5 504 511 2-s2.0-50549102898 10.1016/j.coi.2008.05.007
216. Peggs K. S., Quezada S. A., Chambers C. A., Korman A. J., Allison J. P., Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. Journal of Experimental Medicine 2009 206 8 1717 1725 2-s2.0-68149155982 10.1084/jem.20082492
217. Attia P., Maker A. V., Haworth L. R., Rogers-Freezer L., Rosenberg S. A., Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma. Journal of Immunotherapy 2005 28 6 582 592 2-s2.0-27444435581 (Pubitemid 41533092)
218. de la Cruz-Merino L., Grande-Pulido E., Albero-Tamarit A., De Villena M. E. C. M., Cancer and immune response: old and new evidence for future challenges. Oncologist 2008 13 12 1246 1254 2-s2.0-58749109167 10.1634/theoncologist.2008-0166
219. + myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clinical Cancer Research 2005 11 18 6713 6721 2-s2.0-25144466458 10.1158/1078-0432.CCR-05-0883 (Pubitemid 41339014)
220. Lake R. A., Robinson B. W. S., Immunotherapy and chemotherapya practical partnership. Nature Reviews Cancer 2005 5 5 397 405 2-s2.0-18344375283 10.1038/nrc1613 (Pubitemid 40637831)
221. Lake R. A., van der Most R. G., A better way for a cancer cell to die. The New England Journal of Medicine 2006 354 23 2503 2504 2-s2.0-33744961742 10.1056/NEJMcibr061443 (Pubitemid 43855057)
222. Formenti S. C., Demaria S., Systemic effects of local radiotherapy. The Lancet Oncology 2009 10 7 718 726 2-s2.0-67649359533 10.1016/S1470-2045(09) 70082-8
223. Mantovani A., Allavena P., Sica A., Balkwill F., Cancer-related inflammation. Nature 2008 454 7203 436 444 2-s2.0-47949096781 10.1038/nature07205
224. Reits E. A., Hodge J. W., Herberts C. A., Groothuis T. A., Chakraborty M., Wansley E. K., Camphausen K., Luiten R. M., De Ru A. H., Neijssen J., Griekspoor A., Mesman E., Verreck F. A., Spits H., Schlom J., Van Veelen P., Neefjes J. J., Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. Journal of Experimental Medicine 2006 203 5 1259 1271 2-s2.0-33646704729 10.1084/jem.20052494
225. Coates P. J., Rundle J. K., Lorimore S. A., Wright E. G., Indirect macrophage responses to ionizing radiation: implications for genotype-dependent bystander signaling. Cancer Research 2008 68 2 450 456 2-s2.0-39049141295 10.1158/0008-5472.CAN-07-3050 (Pubitemid 351380071)
226. Wright E. G., Coates P. J., Untargeted effects of ionizing radiation: implications for radiation pathology. Mutation Research 2006 597 1-2 119 132 2-s2.0-33646488069 10.1016/j.mrfmmm.2005.03.035
227. Apetoh L., Ghiringhelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., Mignot G., Maiuri M. C., Ullrich E., Saulnier P., Yang H., Amigorena S., Ryffel B., Barrat F. J., Saftig P., Levi F., Lidereau R., Nogues C., Mira J. P., Chompret A., Joulin V., Clavel-Chapelon F., Bourhis J., André F., Delaloge S., Tursz T., Kroemer G., Zitvogel L., Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Medicine 2007 13 9 1050 1059 2-s2.0-34948820602 10.1038/nm1622 (Pubitemid 47517504)
228. Antoniades J., Brady L. W., Lightfoot D. A., Lymphangiographic demonstration of the abscopal effect in patients with malignant lymphomas. International Journal of Radiation Oncology Biology Physics 1977 2 1-2 141 147 2-s2.0-0017365178 (Pubitemid 8086045)
229. Ohba K., Omagari K., Nakamura T., Ikuno N., Saeki S., Matsuo I., Kinoshita H., Masuda J., Hazama H., Sakamoto I., Kohno S., Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut 1998 43 4 575 577 2-s2.0-7344232177 (Pubitemid 28462047)
230. Rees G. J. G., Ross C. M. D., Abscopal regression following radiotherapy for adenocarcinoma. British Journal of Radiology 1983 56 661 63 66 2-s2.0-0020657530 (Pubitemid 13177584)
231. Camphausen K., Moses M. A., Ménard C., Sproull M., Beecken W. D., Folkman J., O'Reilly M. S., Radiation abscopal antitumor effect is mediated through p53. Cancer Research 2003 63 8 1990 1993 2-s2.0-0345269096 (Pubitemid 36460868)
232. Abbas A., Lichtman A., Pillai S., Immunity to tumors. Cellular and Molecular Immunology 2007 Philadelphia, Pa, USA Saunders Elsevier 397 417
233. Sharpe A. H., Abbas A. K., T-cell costimulationbiology, therapeutic potential, and challenges. The New England Journal of Medicine 2006 355 10 973 975 2-s2.0-33748428203 10.1056/NEJMp068087 (Pubitemid 44343539)
234. Carreno B. M., Bennett F., Chau T. A., Ling V., Luxenberg D., Jussif J., Baroja M. L., Madrenas J., CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. Journal of Immunology 2000 165 3 1352 1356 2-s2.0-0034254301 (Pubitemid 30604565)
235. Robert C., Ghiringhelli F., What is the role of cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma? Oncologist 2009 14 8 848 861 2-s2.0-70249083099 10.1634/theoncologist.2009-0028
236. Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., Van Den Eertwegh A. J. M., Lutzky J., Lorigan P., Vaubel J. M., Linette G. P., Hogg D., Ottensmeier C. H., Lebbé C., Peschel C., Quirt I., Clark J. I., Wolchok J. D., Weber J. S., Tian J., Yellin M. J., Nichol G. M., Hoos A., Urba W. J., Improved survival with ipilimumab in patients with metastatic melanoma. The New England Journal of Medicine 2010 363 8 711 723 2-s2.0-77954801079 10.1056/NEJMoa1003466
237. Robert C., Thomas L., Bondarenko I., O'Day S., Weber J., Garbe C., Lebbe C., Baurain J. F., Testori A., Grob J. J., Davidson N., Richards J., Maio M., Hauschild A., Miller W. H., Gascon P., Lotem M., Harmankaya K., Ibrahim R., Francis S., Chen T. T., Humphrey R., Hoos A., Wolchok J. D., Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. The New England Journal of Medicine 2011 364 26 2517 2526 2-s2.0-79959772576 10.1056/NEJMoa1104621
238. Bashey A., Medina B., Corringham S., Pasek M., Carrier E., Vrooman L., Lowy I., Solomon S. R., Morris L. E., Holland H. K., Mason J. R., Alyea E. P., Soiffer R. J., Ball E. D., CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009 113 7 1581 1588 2-s2.0-61849165013 10.1182/blood-2008-07-168468
239. Azuma T., Yao S., Zhu G., Flies A. S., Flies S. J., Chen L., B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008 111 7 3635 3643 2-s2.0-43549115533 10.1182/blood-2007-11-123141
240. Parekh V. V., Lalani S., Kim S., Halder R., Azuma M., Yagita H., Kumar V., Wu L., Van Kaer L., PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells. Journal of Immunology 2009 182 5 2816 2826 2-s2.0-64849116017 10.4049/jimmunol.0803648
241. Aldinucci D., Gloghini A., Pinto A., Colombatti A., Carbone A., The role of CD40/CD40L and interferon regulatory factor 4 in Hodgkin lymphoma microenvironment. The Leukemia & Lymphoma 2012 53 2 195 201
242. Fonsatti E., Maio M., Altomonte M., Hersey P., Biology and clinical applications of CD40 in cancer treatment. Seminars in Oncology 2010 37 5 517 523 2-s2.0-78449262545 10.1053/j.seminoncol.2010.09.002
243. Aldinucci D., Rapana' B., Olivo K., Lorenzon D., Gloghini A., Colombatti A., Carbone A., IRF4 is modulated by CD40L and by apoptotic and anti-proliferative signals in Hodgkin lymphoma. British Journal of Haematology 2010 148 1 115 118 2-s2.0-72249086157 10.1111/j.1365-2141.2009.07945.x
244. Advani R., Forero-Torres A., Furman R. R., Rosenblatt J. D., Younes A., Ren H., Harrop K., Whiting N., Drachman J. G., Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. Journal of Clinical Oncology 2009 27 26 4371 4377 2-s2.0-70349334508 10.1200/JCO.2008.21.3017
245. Ansell S. M., Hurvitz S. A., Koenig P. A., Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clinical Cancer Research 2009 15 20 6446 6453
246. Younes A., Oki Y., McLaughlin P., Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphoma. Blood 2012 119 18 4123 4128
247. Younes A., Romaguera J., Hagemeister F., McLaughlin P., Rodriguez M. A., Fiumara P., Goy A., Jeha S., Manning J. T., Jones D., Abruzzo L. V., Medeiros L. J., A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 2003 98 2 310 314 2-s2.0-0038345400 10.1002/cncr.11511 (Pubitemid 36828455)
248. Oki Y., Pro B., Fayad L. E., Romaguera J., Samaniego F., Hagemeister F., Neelapu S., McLaughlin P., Goy A., Younes A., Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008 112 4 831 836 2-s2.0-39049155001 10.1002/cncr.23237 (Pubitemid 351240577)
249. Younes A., Wong F., Experience with 90Y-ibritumomab tiuxetan for relapsed classical Hodgkin lymphoma. Annals of Oncology 2009 20 6 1147 1148
250. Ambrose L. R., Morel A. S., Warrens A. N., Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab. Blood 2009 114 14 3052 3055 2-s2.0-70449483876 10.1182/blood-2009-02-203075
251. Peggs K. S., Sureda A., Qian W., Caballero D., Hunter A., Urbano-Ispizua A., Cavet J., Ribera J. M., Parker A., Canales M., Mahendra P., Garcia-Conde J., Milligan D., Sanz G., Thomson K., Arranz R., Goldstone A. H., Alvarez I., Linch D. C., Sierra J., MacKinnon S., Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes. British Journal of Haematology 2007 139 1 70 80 2-s2.0-34548544801 10.1111/j.1365-2141.2007.06759.x (Pubitemid 47389932)
252. Fehniger T. A., Larson S., Trinkaus K., A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2011 118 19 5119 5125
253. Chanan-Khan A. A., Cheson B. D., Lenalidomide for the treatment of B-cell malignancies. Journal of Clinical Oncology 2008 26 9 1544 1552 2-s2.0-41149168649 10.1200/JCO.2007.14.5367
254. Corazzelli G., De Filippi R., Capobianco G., Frigeri F., De Rosa V., Iaccarino G., Russo F., Arcamone M., Becchimanzi C., Crisci S., Marcacci G., Amoroso B., Lastoria S., Pinto A., Tumor flare reactions and response to lenalidomide in patients with refractory classic Hodgkin lymphoma. American Journal of Hematology 2010 85 1 87 90 2-s2.0-74049139971 10.1002/ajh.21571
255. Fehniger T., Larson S., Trinkaus K., A phase II multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood 2009 114 3693
256. Kuruvilla J., Taylor D., Wang L., Blattler C., Keating A., Crump M., Phase II trial of lenalidomide in patients with relapsed or refractory Hodgkin lymphoma. Blood 2008 112 3052
257. Younes A., Bartlett N. L., Leonard J. P., Kennedy D. A., Lynch C. M., Sievers E. L., Forero-Torres A., Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. The New England Journal of Medicine 2010 363 19 1812 1821 2-s2.0-78049515807 10.1056/NEJMoa1002965
258. Gualberto A., Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. Expert Opinion on Investigational Drugs 2012 21 2 205 216
259. Redmond W. L., Ruby C. E., Weinberg A. D., The Role of OX40-mediated Co-stimulation in T-cell activation and survival. Critical Reviews in Immunology 2009 29 3 187 201 2-s2.0-67650290300
260. Jensen S. M., Maston L. D., Gough M. J., Ruby C. E., Redmond W. L., Crittenden M., Li Y., Puri S., Poehlein C. H., Morris N., Kovacsovics-Bankowski M., Moudgil T., Twitty C., Walker E. B., Hu H. M., Urba W. J., Weinberg A. D., Curti B., Fox B. A., Signaling through OX40 enhances antitumor immunity. Seminars in Oncology 2010 37 5 524 532 2-s2.0-78449237498 10.1053/j.seminoncol. 2010.09.013
261. Buglio D., Khaskhely N. M., Voo K. S., Martinez-Valdez H., Liu Y. J., Younes A., HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma. Blood 2011 117 10 2910 2917 2-s2.0-79953084657 10.1182/blood-2010-08-303701
262. Buglio D., Younes A., Histone deacetylase inhibitors in Hodgkin lymphoma. Investigational New Drugs 2010 28 supplement 1 S21 S27 2-s2.0-78651378094 10.1007/s10637-010-9588-y
263. Younes A., Wong F., Experience with 90Y-ibritumomab tiuxetan for relapsed classical Hodgkin lymphoma. Annals of Oncology 2009 20 6 1147 1148 2-s2.0-66149155829 10.1093/annonc/mdp277
264. Hallek M., Cheson B. D., Catovsky D., Caligaris-Cappio F., Dighiero G., Döhner H., Hillmen P., Keating M. J., Montserrat E., Rai K. R., Kipps T. J., Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008 111 12 5446 5456 2-s2.0-45149100665 10.1182/blood-2007-06-093906
265. Böll B., Borchmann P., Topp M. S., Hänel M., Reiners K. S., Engert A., Naumann R., Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphoma. British Journal of Haematology 2010 148 3 480 482 2-s2.0-74049104854 10.1111/j.1365-2141.2009.07963.x
266. Deutsch Y. E., Tadmor T., Podack E. R., Rosenblatt J. D., CD30: an important new target in hematologic malignancies. The Leukemia & Lymphoma 2011 52 9 1641 1654
267. Okeley N. M., Miyamoto J. B., Zhang X., Sanderson R. J., Benjamin D. R., Sievers E. L., Senter P. D., Alley S. C., Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clinical Cancer Research 2010 16 3 888 897 2-s2.0-76049122850 10.1158/1078-0432.CCR-09-2069